<SEC-DOCUMENT>0001144204-17-027431.txt : 20170515
<SEC-HEADER>0001144204-17-027431.hdr.sgml : 20170515
<ACCEPTANCE-DATETIME>20170515160125
ACCESSION NUMBER:		0001144204-17-027431
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20170515
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20170515
DATE AS OF CHANGE:		20170515

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Synthetic Biologics, Inc.
		CENTRAL INDEX KEY:			0000894158
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				133808303
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12584
		FILM NUMBER:		17844086

	BUSINESS ADDRESS:	
		STREET 1:		617 DETROIT STREET, SUITE 100
		CITY:			ANN ARBOR
		STATE:			MI
		ZIP:			48104
		BUSINESS PHONE:		(734) 332-7800

	MAIL ADDRESS:	
		STREET 1:		155 GIBBS STREET
		STREET 2:		SUITE 412
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ADEONA PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20081027

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PIPEX PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20061214

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SHEFFIELD PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19970730
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>v467077_8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FORM 8-K<BR>
CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Pursuant to Section 13 or 15(d)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>of the Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Date of Report (Date of earliest event reported):
May 15, 2017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SYNTHETIC BIOLOGICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 27.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nevada</FONT></TD>
    <TD STYLE="width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 32%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-12584</FONT></TD>
    <TD STYLE="width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 32%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13-3808303</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State or other jurisdiction of incorporation)</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission File No.)</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(IRS Employer Identification No.)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">9605 Medical Center Drive, Suite 270</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Rockville, MD 20850</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Address of principal executive offices
and zip code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Registrant&rsquo;s telephone number, including
area code: (301) 417-4364</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">N/A</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Former name or former address, if changed
since last report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&#168;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&#168;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 8.01.&nbsp;&nbsp;&nbsp;Other Events</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 11, 2017, Synthetic Biologics, Inc.,
a Nevada corporation, (the &ldquo;Registrant&rdquo;) issued the attached press release that included notification that the U.S.
Food and Drug Administration (FDA) has granted a Breakthrough Therapy Designation for SYN-004 (ribaxamase) for the prevention of
<I>Clostridium difficile</I> infection. A copy of the press release is attached as Exhibit 99.1 to this Report on Form 8-K and
incorporated herein by reference.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 9.01.&nbsp;&nbsp;&nbsp;Financial Statements and Exhibits. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d) Exhibits</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="width: 10%; border-bottom: Black 1pt solid">Exhibit<BR>
        No.</TD>
    <TD STYLE="width: 2%; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 88%; border-bottom: Black 1pt solid">Description</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD NOWRAP STYLE="vertical-align: top">99.1 </TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">Synthetic Biologics, Inc. press release dated May
11, 2017</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:&nbsp;&nbsp;May 15, 2017</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-right: 1.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SYNTHETIC BIOLOGICS, INC.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-right: 1.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Registrant)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 51%; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 5%; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 44%; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Steven Shallcross</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Steven Shallcross</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:&nbsp;&nbsp;Chief Financial Officer</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v467077_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="logo.jpg" ALT=""><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SYN-004 (Ribaxamase) Receives Breakthrough
Therapy Designation from U.S. Food and Drug</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Administration for Prevention of <I>Clostridium difficile</I> Infection </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>-- <I>FDA Action Marks First Breakthrough
Therapy Designation for Clinical Program </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>Designed to Prevent Primary Clostridium
difficile Infection</I> --</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>-- Type-B Meeting Anticipated to Discuss
Potential for Expedited Drug Development Strategy --</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>&nbsp;&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>For Immediate Release</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Rockville, MD, May 11, 2017 &ndash;</B>
Synthetic Biologics, Inc. (NYSE MKT: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to
protect and restore the health of patients, today announced that the U.S. Food and Drug Administration (FDA) has granted a Breakthrough
Therapy Designation for SYN-004 (ribaxamase) for the prevention of <I>Clostridium difficile</I> infection. SYN-004 (ribaxamase)
is the Company&rsquo;s first-in-class oral enzyme designed to protect the gut microbiome from disruption caused by certain intravenous
(IV) beta-lactam antibiotics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Breakthrough Therapy Designation is
based on data from the successful Phase 2b clinical trial of ribaxamase, which met its primary endpoint of significantly reducing
CDI. FDA Breakthrough Therapy Designation is intended to expedite development and review timelines when preliminary clinical evidence
indicates that a drug may demonstrate substantial improvement on one or more clinically significant endpoints over available therapies
for serious or life threatening diseases. If approved by the FDA, SYN-004 (ribaxamase) would be the first available drug designed
to prevent <I>Clostridium difficile</I> infection by protecting the gut microbiome from antibiotic-mediated dysbiosis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;We are delighted by the FDA&rsquo;s
recognition of ribaxamase&rsquo;s potential to prevent CDI, and the dire need to fill the current void of an approved intervention,&rdquo;
said Jeffrey Riley, President and Chief Executive Officer. &ldquo;Following this announcement, we have been asked and anticipate
requesting a Type-B multidisciplinary meeting with the Agency for a comprehensive discussion on the overarching, high-level drug
development plan and pathway to licensure for ribaxamase. We look forward to working closely with the FDA throughout the development
and review process and remain dedicated to bringing this potentially paradigm-shifting approach to antibiotic therapy to patients
in critical need.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About <I>Clostridium difficile</I> Infection</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Clostridium difficile</I> infection
is the number one hospital acquired infection in the U.S., with more than 453,000<SUP>1</SUP> patients diagnosed annually. CDI
results in approximately 29,000<SUP>1</SUP> deaths, $1.5 billion<SUP>1</SUP> in additional healthcare costs, as well as significant
and sometimes prolonged illness.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About SYN-004 (ribaxamase) and the Phase
2b Study</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">SYN-004 (ribaxamase) is a first-in-class
oral enzyme designed to degrade certain IV beta-lactam antibiotics within the GI tract and maintain the natural balance of the
gut microbiome for the prevention of CDI, pathogenic overgrowth and the emergence of antimicrobial resistance (AMR). Synthetic
Biologics initiated a Phase 2b proof-of-concept clinical trial intended to evaluate the effectiveness of ribaxamase to prevent
the onset of primary <I>C. difficile</I> infection (CDI), antibiotic-associated diarrhea (AAD) and the emergence of antimicrobial
resistance (AMR) in patients hospitalized with a lower respiratory infection and receiving IV ceftriaxone. Results from this trial
indicate that patients receiving ribaxamase achieved a 71.4% relative risk reduction (p-value=0.045) in CDI rates compared to patients
receiving placebo. Analysis of the data also demonstrated a significant reduction in new colonization by vancomycin-resistant enterococci
(VRE) for patients receiving ribaxamase compared to placebo (p-value=0.0002). Adverse events reported during this trial were comparable
between treatment and placebo arms. Analysis of data from several exploratory endpoints designed to evaluate ribaxamase&rsquo;s
ability to prevent the emergence and proliferation of AMR in the gut microbiome is ongoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Synthetic Biologics, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Synthetic Biologics, Inc. (NYSE MKT: SYN)
is a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients.
The Company&rsquo;s lead candidates poised for Phase 3 development are: (1) SYN-004 (ribaxamase) which is designed to protect the gut
microbiome from the effects of certain commonly used intravenous (IV) beta-lactam antibiotics for the prevention of <I>C. difficile</I>
infection, pathogenic overgrowth and the emergence of antimicrobial resistance (AMR), and (2) SYN-010 which is intended to reduce
the impact of methane producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation
(IBS-C). The Company is also developing preclinical stage monoclonal antibody therapies for the prevention and treatment of pertussis
and novel discovery stage biotherapeutics for the treatment of phenylketonuria (PKU). For more information, please visit Synthetic
Biologics&rsquo; website at www.syntheticbiologics.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: windowtext"><I>This
release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some
cases, forward-looking statements can be identified by terminology such as &ldquo;may,&rdquo; &ldquo;should,&rdquo; &ldquo;potential,&rdquo;
&ldquo;continue,&rdquo; &ldquo;expects,&rdquo; &ldquo;anticipates,&rdquo; &ldquo;intends,&rdquo; &ldquo;plans,&rdquo; &ldquo;believes,&rdquo;
&ldquo;estimates&rdquo; and similar expressions and include statements regarding the potential of ribaxamase to prevent CDI, </I></FONT><I>the
anticipated request for a Type-B multidisciplinary meeting with the Agency for a comprehensive discussion on the overarching, high-level
drug development plan and pathway to licensure for ribaxamase, the intended expedited development of ribaxamase due to Breakthrough
Therapy Designation<FONT STYLE="color: windowtext">, the </FONT>potentially paradigm-shifting approach to antibiotic therapy to
patients in critical need, and <FONT STYLE="color: windowtext">the ability of SYN-004 to protect the gut microbiome from the </FONT>disruption
caused by certain intravenous (IV) beta-lactam antibiotic and the industry data regarding the expected incidence and economic burden
of CDI<FONT STYLE="color: windowtext">. These forward-looking statements are based on management&rsquo;s expectations and assumptions
as of the date of this press release and are subject to a number of risks and uncertainties that could cause actual results to
differ materially from those set forth or implied by any forward-looking statements. Important factors that could cause actual
results to differ materially from current expectations include, among others, Synthetic Biologics&rsquo; product candidates demonstrating
safety and effectiveness, as well as results that are consistent with prior results, Synthetic Biologics&rsquo; ability to initiate clinical
trials and if initiated, to complete them on time and achieve desired results and benefits, Synthetic Biologics&rsquo; clinical trials
continuing enrollment as expected, Synthetic Biologics&rsquo; ability to obtain regulatory approvals for commercialization of product
candidates or to comply with ongoing regulatory requirements, regulatory limitations relating to Synthetic Biologics&rsquo; ability to
promote or commercialize its product candidates for specific indications, acceptance of its product candidates in the marketplace
and the successful development, marketing or sale of Synthetic Biologics&rsquo; products by competitors that render Synthetic Biologics&rsquo;
products obsolete or non-competitive, Synthetic Biologics&rsquo; ability to maintain its license agreements, the continued maintenance
and growth of Synthetic Biologics&rsquo;</FONT></I><FONT STYLE="color: windowtext">&nbsp;<I>patent estate, Synthetic Biologics becoming
and remaining profitable, Synthetic Biologics&rsquo;</I>&nbsp;<I>ability to establish and maintain collaborations, Synthetic Biologics&rsquo;</I>&nbsp;<I>ability
to obtain or maintain the capital or grants necessary to fund its research and development activities, a loss of any of Synthetic
Biologics&rsquo;</I>&nbsp;<I>key scientists or management personnel,</I>&nbsp;<I>and other factors described in Synthetic Biologics&rsquo;
Annual Report on Form 10-K for the year ended December 31, 2016 and its other filings with the SEC, including subsequent periodic
reports on Forms 10-Q and 8-K.The information in this release is provided only as of the date of this release, and Synthetic Biologics
undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future
events, or otherwise, excepted as required by law.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>For further information, please contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Synthetic Biologics, Inc. (Corporate and
Investors)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Vincent I. Perrone, Director Corporate Communication, (240)
660-2000, info@syntheticbiologics.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Feinstein Kean Healthcare (Media)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Gregory Kelley, Senior Vice President, (404) 836-2302, gregory.kelley@fkhealth.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"># # #</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" !1 1T# 2(  A$! Q$!_\0
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M?U/JZBH[:YCO;:.:%TEBE4.CHVY74\@@]P:DK^G$TU='Y6[K1A1113 ****
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M2_8H\!_LY?&#PQX[\,6NHP:[\6-0U74?$'VB\:>"2=/L[!XD;_5Y,KY ..F
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M5_VM/A?\"?$$>E>-?B%X-\)ZG-;B[CM-6U>"SF>$DJ) LC E<JPSTX->=_\
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MD6=E9Q!%'"1PQJ, >@  K/%5)TJ<:5]=_P#(O#PC4G*I;0_F0_99_9?UIO\
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MD"1G!91NA"_+C@GO7U7\.KV#5O\ @U<U6VM9X;BXL_"-]]HBBD#/!C4Y6.\
MY7Y>>>W-<9_P:R_%SPMX'\+_ !BTC6O$6B:/J>H:GI<]K;7U[';R72>5-'F,
M.1O^<A3C."R^HK'GG&A44>C-.6,JL'+JB?\ X.Q_N? W_?UG_P!!LZX/X6_\
M$"M6_:^_8)\-?%;6OBYJ]]XKN/",=WX=T::Q673=.M(X2UO8[F;>HV@ L@4!
MF)VMU/:?\'8.J6UU<_!.VBN;>2YMVU@S0I*K21!EM-I90<@'!P2.<'TK[O\
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M(>?L1_![2[6;7_CWK>DQ:K/%:6J_\)+ICR7,DK!$"(D!9LEAR!@9R2!S3O\
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MH7V6YM[DP>!X8I1#*KF)_M5U\K8/#<C@\\BIPU2;Q3395:$5ATUY'T;_ ,'
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MW%M;!U-X0J1E\I1_5:';XH5:&*X8I8VE\,Y0E'YQE^A]!4445_5Y_-84444
M?-7[=7_!)SX-_P#!04QWWC31+BP\46T0A@\0Z/,+7450=$=L%)D'99%;';&:
M^+8O^#37X?)K E/Q;\8?9 V?+&D68FQGIYF,=.^VOUGHK>&*JP5HRT,I4*<G
M>2/"?V&?^"<OPN_X)Z>#+O2_A]I,ZWFJE6U/6-0F^T:CJ17.T228 "+DX1 J
MC).,DFO(O^"UO[6WP@^'7[$WQ0\"^,=>T74/$^NZ(UG8>&(KQ3J4US* ;:7R
MAED1'"R[V 4",\YP#]IU\.?M@_\ !!/X5?ML?M.ZE\4/%GB?Q];ZCK*6\5Y8
MV%Y;Q6[)!$L2*A,+.@VKS\Q.22"*=*<74YZK8JD6H<M-'RE_P:P?LI,S^/?C
M3J=L>B^%=#E=.&P5FO)%_P"!>0F1_=<>M?J1^UW^S5IG[8?[-_BOX::UJ.I:
M3I?BVU6TN+O3RHN85$B293<"N24 Y!X)K>^"?P5\,?LZ_"O1?!7@W2;?0_#7
MA^W%M96<&=L:Y))).2S,Q+,Q)+,Q)))KSK_@HSX]UOX8_L<>,=;\.ZE=:1K-
ME';FWN[9@LD1:YB4X)]02/QKES3,51IU,;):03EYVBKGI9%E$L=BZ&6TVE*K
M*,+O:\FE=^6I\2O_ ,&J'P@>'9_PL?XE*N,#!LAM],?N:]6_;(_X(!_#K]M+
MXXOX[U[QMXYTO47TNRTGR+%K;R1';1"-6&^)FRP&3SC-=7_P3P^.OB#XA_'C
MQ7H-I\0-3^)?@73=$M;O^T]5MXX+NTU"1ANA3"JSQ[0_)7 *@9_O=S_P5$\=
M:W\/?V>=(O=!U?4M%O)/%6EVSSV-PT$CQ/*0Z%E(.UAU'0UY5/BOVF72S.-[
M0YM+KH[.S3::TW3/I*_ %6CGU+A^<X\]3DUM)6YU=<T9)232>J:3//\ ]AS_
M ((A_#3]B'_A8$%IK?B3QCI?Q)T8:%K&GZV8#!);Y?=@1(ARP<@G/3&,5X'#
M_P &LGPXT;XJV.NZ1\4/'%AI>EZC#J%GI\EI:SS6YBE61$%P0"0"H&2N[WS7
MZAZM>G3=*N;@+N,$3R 'O@$_TK\]_AU\;OBEIG@?X7?&*^^(VL:K'X]\:+H>
MH>&9H(ETR&VEN)8L1 +N5E$>0<]QZ'.V9\22P%2*DI2YDV[6TBG%-N[7\RT6
MIR\.\%3SBC4J4YQAR-12ES>].49R459.UU3EK*RO;N+^TO\ \&Y7PQ_:>_:$
M\7_$75O'?CZPU3QCJ#:A<V]JUKY$#%5&Q-T1;:-O&2>IK5\*?\&^OPX\)?LC
M^,O@]#XW\=2:%XUUVRU^[NW:V^TPRVHPJ)B+9L;^+*D^]?9G[0&M7?ASX#>-
MM0L+B2TOK#0+ZXMIXSAX9$MY&5U]P0"/I7*_L+>,=5^(/[(/P^UK6[^XU35M
M2T>*>ZNYSF2X<YRS'UKL>;36*6"N[\O-Y:-+]3R(Y%?+99IIRJ:IVUO>492O
MVM9'P]X9_P"#7+X3>%_%.E:M#\1?B0\^D7L%]$K-9@%XI%< XAS@E<''8FO:
M_P#@H-_P0[^$G[?WC%_%EY+JW@OQM/&L5UJ^C>7C454 +]HA=2DC!1@.-K8
M!)  'HO[?7Q#\4:1J7PO\&>%]?NO"LOQ#\2KI5YJMI&K75K J%V$6X$!B<<^
MWO4/[!_CCQ6_CWXM> O$WB6]\7)\/M:M[73]4OD47DT4T1D*R%0 VTKP<=SV
MP!Q/B1_V@L':5[VYM+7Y>>V]_A5[VMT/7CP7/^Q7F_/&UN;D][FY/:*ES7MR
M_&[6O>VI\E?!O_@U;^#W@GQ1#?>+/&OC'QE9PL&_L^..#2X9\'.)&B!D*GN%
M=3[U]O?MF?L)^!/VX_V=V^&_B^"]BTJ!XI].N[.;;>:7/$I6.:-V#9(4LI#
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M+"U'NE?E^5FG%>6J[)'[16=G#IUI%;V\4<$$*"...-0J1J!@  <  =J^"?\
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M*Y_D!U)/  )/2OV$_9&_9XM_V9?@CIGAM7CN-1YNM3N4'%Q=/C>1WVC 5?\
M945@?LD_L*>#_P!DK3FFT\2:QXDN8_+NM9NT'G,O=(U'$2>PY/<FO;*_=^ N
M!?['3Q>+LZTE:RVBNWFWU?R76_\ */BKXET\_E'+\MNL-!WN]'.6R=ND5T3U
M=[OHE!8Z9;Z:9C!"D1N93-*5',CG +'U. !] !VJ>BBOTI)+1'XTVV[L****
M!!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
?%%%% !1110 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
